Welcome to the 10th Neurodegenerative Drug Development Summit

With Biogen’s Aducanumab approval dramatically overhauling the regulatory landscape for neurodegenerative disease, the beta amyloid revival is in full swing with investment pouring in across multiple neurodegenerative diseases. With this, biopharma across the globe are racing to harness the exhilarating momentum of the past year and turbocharge their neurodegenerative disease drug development in 2022 and beyond.  

From leveraging data from clinical samples to catalyze the next generation of therapies against Alzheimer’s and Parkinson’s disease, learning how to justify investment in rare neurodegenerative diseases, through to taking a multi-omic approach to target discovery, the 10th Neurodegenerative Drug Development Summit will siphon critical insights from leading industry experts to accelerate therapeutic development through to approval for NDD patients around the world.

Join us to witness this neuroscience renaissance head on and meet with the biggest neurodegenerative KOL’s across this exceedingly challenging and exciting field, as we fight to unravel the complexities of neurodegenerative drug development. Join 200+ neurodegenerative drug development experts to learn from those revolutionising this space into 2022 and beyond.

Download the draft agenda to learn more or register your place.

"High quality speakers and multiple opportunities to meet the other participants. Highly informative and interactive"
Michael Ruff, President, Creative Bio-Peptides Inc.

"A very good overview of the state of the art issues that are confronting the field of neurodegeneration"
Brett Skolnick, Executive Director - Clinical Development, Gossamer Bio

"NDD provided a great opportunity for discussion, feedback, and networking alongside an all star speaker line-up"
Samantha Hutten, Senior Associate Director - Research Partnerships & Research Programs, The Michael J. Fox Foundation for Parkinson's Research

"Great update on the current state of affairs of neurodegenerative research"
Mark A. Reed, CSO, Treventis Group